Literature DB >> 508567

Isoenzymes of hexokinase, 6-phosphogluconate dehydrogenase, phosphoglucomutase and lactate dehydrogenase in uterine cancer.

M J Marshall, F E Neal, D M Goldberg.   

Abstract

Electrophoresis of cytosol prepared from normal and malignant tissue samples of uterine cervix and endometrium revealed interesting differences which may be relevant to the characteristic alterations in glucose metabolism associated with tumour development. Hexokinase II was detected in 30% of the cancer material from both sources, but in none of the samples of normal cervix. A duplet band of 6-phosphogluconate dehydrognease was seen in the majority of the cancer samples but in no sample of normal cervix; it appeared to be partly due to ageing of the sample, and is not phenotypically related to the malignant process. Analysis of genetic variance for phosphoglucomutase at the PGM1 locus revealed a highly significant excess of the PGM1-1 phenotype in patients with cancer of the endometrium, which may reflect susceptibility to endometrial cancer in patients with this phenotype. At the PGM2 locus, samples of malignant cervix were deficient in "Band f" compared with normal cervix samples, all of which showed this band. Conversely, gene products of the PGM3 locus were found in most samples of malignant cervix and a small minority of normal cervix samples. Compared with the isomorphic distribution of lactate dehydrogenase enzymes in normal uterine tissue, cancers showed a shift towards either a more anodal or a more cathodal pattern. The former may be associated with tumours enjoying a good oxygen supply, and the latter with tumours which, because of their depth or poor blood supply have to function under less aerobic conditions.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 508567      PMCID: PMC2010033          DOI: 10.1038/bjc.1979.192

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  LACTIC DEHYDROGENASE IN HUMAN NEOPLASTIC TISSUES.

Authors:  R D GOLDMAN; N O KAPLAN; T C HALL
Journal:  Cancer Res       Date:  1964-04       Impact factor: 12.701

2.  Typing of the common phosphoglucomutase variants using isoelectric focusing--a new interpretation of the phosphoglucomutase system.

Authors:  J E Bark; M J Harris; M Firth
Journal:  J Forensic Sci Soc       Date:  1976-04

3.  Control of rat adipose tissue hexokinase isoenzymes by sugars during in vitro incubation.

Authors:  R S Bernstein
Journal:  Proc Soc Exp Biol Med       Date:  1977-11

4.  Activities and isoenzyme patterns of some enzymes of glucose metabolism in human primary malignant hepatoma.

Authors:  D Balinsky; E Cayanis; E W Geddes; I Bersohn
Journal:  Cancer Res       Date:  1973-02       Impact factor: 12.701

5.  Separation and quantitation of lactic dehydrogenase isoenzymes by disc electrophoresis.

Authors:  A A Dietz; T Lubrano
Journal:  Anal Biochem       Date:  1967-08       Impact factor: 3.365

6.  Increased synthesis of lactate dehydrogenase "H" subunit by a malignant tumor.

Authors:  A R Henderson; D Ahmad; D McKenzie
Journal:  Clin Chem       Date:  1974-11       Impact factor: 8.327

7.  Isozyme variations in human malignant melanoma.

Authors:  R Prasad; M M Romsdahl; C R Shaw; D M Mumford; J L Smith
Journal:  Cancer Res       Date:  1974-06       Impact factor: 12.701

8.  Isoenzymes of hexokinase in the developing, normal and neoplastic human brain.

Authors:  M J Bennett; W R Timperley; C B Taylor; A S Hill
Journal:  Eur J Cancer       Date:  1978-02       Impact factor: 9.162

  8 in total
  3 in total

1.  The value of lactate dehydrogenase as a nonspecific tumour marker for seminoma of the testis.

Authors:  A G Robertson; G Read
Journal:  Br J Cancer       Date:  1982-12       Impact factor: 7.640

Review 2.  Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches.

Authors:  Karen G de la Cruz-López; Leonardo Josué Castro-Muñoz; Diego O Reyes-Hernández; Alejandro García-Carrancá; Joaquín Manzo-Merino
Journal:  Front Oncol       Date:  2019-11-01       Impact factor: 6.244

3.  A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.

Authors:  Maureen Elizabeth Trudeau; Judith-Anne W Chapman; Baoqing Guo; Mark J Clemons; Rebecca A Dent; Roberta A Jong; Harriette J Kahn; Kathleen I Pritchard; Lei Han; Patti O'Brien; Lois E Shepherd; Amadeo M Parissenti
Journal:  Springerplus       Date:  2015-10-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.